JAN 10, 2017 1:30 PM PST

Existing Drug Halts Triple-Negative Breast Cancer Metastasis

WRITTEN BY: Xuan Pham

For aggressive, intractable triple-negative breast cancers, there’s still hope. Researchers at the Mayo Clinic found that a pre-existing drug that’s shown positive effects in another type of breast cancer may also halt the spread of triple-negative cancer.

Breast cancer is generally classified into 3 subtypes according to the presence or absence of three receptors: estrogen, progesterone, and the epidermal growth factor receptor 2 (HER2). Typically, breast cancers positive for estrogen or HER2 respond well to hormone therapy. However, cancers that are negative for these receptors have proven more difficult to treat and manage. In particular, cancers that are negative for all three receptors, known as triple negative breast cancer, are most notorious for evading treatment.

In studying how the receptor-positive breast cancers respond to treatment, researchers at the Mayo Clinic found that a class of inhibitors may also be effective against receptor-negative breast cancers.

The drugs are known as CDK 4/6 inhibitors, and they work by blocking the enzyme cyclin-dependent kinases (CDKs). Many cancers have high CDK activity, which promotes the unregulated proliferation of cancer cells. Inhibitors of this enzyme pathway have been shown to be effective against ER-positive and HER2-positive breast cancers. Recently, Palbociclib – another CDK 4/6 inhibitor – showed promising Phase II trial results in patients with HER2-negative breast cancer too.

CDK 4/6 inhibitors have previously been tested in triple-negative breast cancers with disappointing results – these drugs didn’t seem to reduce the growth of these cancers. But in applying the drugs to a triple-negative breast cancer mouse models, researchers at the Mayo Clinic found that metastasis was halted. In essence the drug stopped the cancer from invading to other parts of the body.

Of note, metastasis is one of the biggest conditions that severely undermines the effectiveness of anticancer treatments. As such, a drug that can halt metastasis is still quite important, even if it can’t reduce the growth of the primary tumor. Perhaps this will lead to combination therapy that targets both the primary tumor and prevent spread to secondary organs, thereby increasing the survival rate.

"These findings may provide a new treatment for the prevention of cancer metastasis. Mayo Clinic is now developing new studies that will focus on the role of CDK 4/6 inhibitors and their potential to inhibit cancer metastasis in women with triple-negative breast cancer who are at highest risk for cancer metastasis,” said Matthew Goetz, the study’s co-author.

Additional sources: MNT, Mayo Clinic

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 18, 2022
Clinical & Molecular DX
New Research Investigates the Molecular Spread of Triple-Negative Breast Cancer
AUG 18, 2022
New Research Investigates the Molecular Spread of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases. TNBC is a term used to describe cas ...
SEP 01, 2022
Clinical & Molecular DX
A Common Bacterial Infection Could Lead to Colon Cancer
SEP 01, 2022
A Common Bacterial Infection Could Lead to Colon Cancer
Infections of the bacterium C. difficile can cause diarrhea and inflammation of the colon called colitis. It is estimate ...
SEP 19, 2022
Genetics & Genomics
CGP: Simplifying the path from tumor to treatment
SEP 19, 2022
CGP: Simplifying the path from tumor to treatment
The promise of NGS in personalized cancer care For years, next-generation sequencing (NGS) has enabled oncologists to id ...
SEP 29, 2022
Cancer
Customer-Led Innovation: Building the CTS Xenon
SEP 29, 2022
Customer-Led Innovation: Building the CTS Xenon
How customers and R&D scientists came together across oceans and a pandemic to create a next-gen cell therapy soluti ...
NOV 03, 2022
Cancer
Uterine Cancer Linked to Hair Straightening Products
NOV 03, 2022
Uterine Cancer Linked to Hair Straightening Products
While uterine cancer represents only 3% of all cancer diagnoses in the United States, it remains the most common female ...
NOV 15, 2022
Genetics & Genomics
Revealing the Mutations that Make Melanoma Immortal
NOV 15, 2022
Revealing the Mutations that Make Melanoma Immortal
Telomeres cap the ends of chromosomes, preventing breakage. Some cancer cells can use those protective caps to their adv ...
Loading Comments...